Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Mitsubishi Tanabe’s Ueno Elected as New JPMA President
The Japan Pharmaceutical Manufacturers Association (JPMA) on May 25 elected Hiroaki Ueno, representative director of Mitsubishi Tanabe Pharma, as its new president for a two-year term. He will take over the helm from Eisai COO Yasushi Okada. Mr Okada stepped…
To read the full story
Related Article
- New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
- Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…